Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. - Wikidata - awgldk - TriplyDB

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

http://www.wikidata.org/entity/Q43043759

about

Systematic review of dasatinib in chronic myeloid leukemia Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned Chronic myeloid leukemia: reminiscences and dreams European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors Treatment Treatment Individualization in Colorectal Cancer Umbilical cord blood transplantation for the treatment of hematologic malignancies Biomarkers for determining the prognosis in chronic myelogenous leukemia Imatinib in chronic myeloid leukemia: an overview Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.Ponatinib in refractory Philadelphia chromosome-positive leukemias.Tyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Chronic Myeloid Leukemia: Long-Term Patient Care and Management Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations The role of observational studies in optimizing the clinical management of chronic myeloid leukemia Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU Secondary mutations as mediators of resistance to targeted therapy in leukemia Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile Dynamics of resistance development to imatinib under increasing selection pressure: a combination of mathematical models and in vitro data Combination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitors A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL Global phosphotyrosine proteomics identifies PKCδ as a marker of responsiveness to Src inhibition in colorectal cancer Dasatinib accelerates valproic acid-induced acute myeloid leukemia cell death by regulation of differentiation capacity A Cell-Based Assay for Measuring Endogenous BcrAbl Kinase Activity and Inhibitor Resistance Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Microfluidic sample preparation for diagnostic cytopathology The value of open access and a patient centric approach to oral oncolytic utilization in the treatment of Chronic Myelogenous Leukemia: A U.S. perspective.Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical tr Increased financial burden among patients with chronic myelogenous leukaemia receiving imatinib in Japan: a retrospective survey.Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor.First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients--systematic review and meta-analysis.Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.Hematologic toxicities of small molecule tyrosine kinase inhibitors.

P2860

Q24596026-E2368B56-E2D9-412B-844C-2524243DDB36 Q24600031-408917EF-0F04-4A7C-AE12-7232FB3DCCD4 Q24607114-AA961BCA-3E6A-4BA5-B746-951390215C97 Q26738514-2B235A69-B6B7-43C5-BF73-67FAE9A633CD Q26748769-EE157CA9-4BE8-4489-8DEA-5D90BDDAFAEC Q26749324-5D440DEF-AA67-4A7C-9955-8545FD8D7A37 Q26766299-02D77499-4B08-4776-8199-E83A3574E855 Q26776215-8966D293-EC77-451F-94A9-39A0C094D949 Q26820829-37741A74-0B7E-4B25-9046-5029E5AFE7F9 Q26824660-B3F9794D-3E68-43A8-A164-C054127D35DF Q26865086-DA58135D-9274-4FD5-8B8A-FAEA36F586FE Q26991817-308E332D-B679-49AB-A78E-C0898AF4FBB3 Q27004032-3812E971-C047-4D49-BF3A-7974DD220248 Q27025242-18BFA8A2-E517-4DE0-BE35-B36BA22AE4CF Q27851628-522A657B-44D7-4C32-BDF8-50F0E17DB324 Q27851660-31467F81-3171-4E99-9572-A44ADC5F9824 Q27851967-62F11EAC-ADA7-4868-B6B3-B7F3D80D3221 Q28075963-198553BC-1540-44D0-B7E4-A1E8B81FBB5D Q28079372-1C0434A0-2311-49A1-9B3D-D7147998F560 Q28085149-65DF08F4-EA14-4651-8BBD-415FC826A351 Q28086893-D8E74242-F370-4015-B78A-B3191F72AC85 Q28087213-2BB89AD2-56D8-419E-92E5-2C7FCD83145E Q28476476-154AC593-4EFD-4542-B533-D777D927A785 Q28478542-00F01331-C1B5-4210-85C2-6618AA180744 Q28484913-212A9E0A-B757-42E2-9127-671B199A2067 Q28534337-F88CBCA7-7BD9-49AE-9A13-8226CE7C20B1 Q28535249-A71562D2-CB34-4F19-87C9-267F8F5C372C Q28539582-6EC3E4B5-E197-48EC-B6B2-9F4853BDD055 Q28553892-B779B16C-F464-4876-88B2-15F2E1179819 Q30242015-0535F0BD-E948-4DA3-8347-96800C740C76 Q30437375-0A57E69A-C68F-47F3-A07A-53A3DFF053D3 Q30491107-1046BBDF-4CFB-4B09-B255-1307318492D9 Q30891587-1D8A7EB6-CD71-480F-8CDB-23D068D29243 Q31033077-1C6E67FB-7654-4B7F-8895-E256D657A92E Q31058336-9D60C9B2-346C-45B7-8F71-54D29E3507B6 Q33276227-18EC5072-35C3-4E85-8718-FBAE00265D08 Q33392977-934A14AB-4DDF-4864-AEC7-0E04C7156DBC Q33396265-4F3C3628-647A-49FA-BAAC-7F1F771A303F Q33397085-DB586C9D-EF63-4AF7-A88D-DA3C5AE05411 Q33398485-0CC3C933-CE03-475B-8587-D32595329A64

P2860

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

http://www.wikidata.org/entity/Q43043759

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

@en

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

@nl

type

label

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

@en

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

@nl

prefLabel

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

@en

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

@nl

P1433

Q43043759-339E558B-15B2-44CD-8220-11FFF5910E57

P1476

Q43043759-25702D14-88E2-4F80-928D-F501FBB2F12D

P2093

Q43043759-0DFB4B32-4F79-4757-B043-0B5608E8A019

Q43043759-35A3235F-F24E-4A23-BC54-4E4E8E1A7571

Q43043759-3B14C41F-0F8C-444E-A6AC-8C8EAAFEC199

Q43043759-44343CF5-E750-4341-A59F-2FE49DB44D63

Q43043759-575F1298-C27F-4AF9-8488-EBAEFB6D14D4

Q43043759-5CD7AFE3-088A-4379-8ECC-4A0214183818

Q43043759-6E6BD187-1A4C-4DB1-9EBF-92AC4223C80A

Q43043759-770FBDDA-BC20-4D3A-9D62-B0EC480E7DAF

Q43043759-8E702444-7EF7-4358-8E47-D0A96E978C2B

Q43043759-9727A24C-E7ED-4FBB-AE5A-F9B7E43BB45C

P304

Q43043759-FB56590A-4CA6-44BC-8EF8-4ACE009BD75C

P31

Q43043759-26C6DB16-7C4F-474D-B573-F1971F0D7C05

P356

Q43043759-2BD05E2F-B7EF-4CDE-BDE4-50EB3A3352BF

P407

Q43043759-F6E74AA6-5B20-4F6E-8F39-260AA4C0869C

P433

Q43043759-EA3B12FB-20FD-45D9-9E56-B2EC6AA06494

P478

Q43043759-65BFC74A-F9B0-4D6A-8ED3-F8FD6C24FF3D

P50

Q43043759-19E71FED-F38B-4246-8A60-3E1AE4EBA506

Q43043759-55B08C5F-3244-4CB7-948F-FD72602E46ED

Q43043759-5ADD30D6-6682-40B3-A88D-AA267252F40C

Q43043759-C7CECA3C-1F1B-4FD7-B3F3-D9EE6F4225E8

P577

Q43043759-CE5D0040-6B01-4DDA-8C0F-923B877878B6

P698

Q43043759-73D703F3-608F-479B-9A53-6CA00E740C49

P921

Q43043759-B0934A23-CBA0-41DD-8F7B-8B7F156F613A

Q43043759-CA8D8DAF-FB68-4011-833E-E751A282E6E1

P356

P1433

The New England Journal of Medicine

P1476

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

@en

P2093

Beatriz Moiraghi

http://www.w3.org/2001/XMLSchema#string

Chao Zhu

http://www.w3.org/2001/XMLSchema#string

Charles Chuah

http://www.w3.org/2001/XMLSchema#string

Concepción Boqué

http://www.w3.org/2001/XMLSchema#string

David Shapiro

http://www.w3.org/2001/XMLSchema#string

Eric Bleickardt

http://www.w3.org/2001/XMLSchema#string

Françoise Huguet

http://www.w3.org/2001/XMLSchema#string

Hirohisa Nakamae

http://www.w3.org/2001/XMLSchema#string

Jiri Mayer

http://www.w3.org/2001/XMLSchema#string

M Brigid Bradley-Garelik

http://www.w3.org/2001/XMLSchema#string

P304

2260-2270

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1002315

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

362

http://www.w3.org/2001/XMLSchema#string

P50

Andreas Hochhaus

Jorge Eduardo Cortes

Hagop Kantarjian

Michele Baccarani

P577

2010-06-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20525995

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia